Induction Therapy, HLA Mismatching, and Standard-Risk Kidney Transplantation
Am J Nephrol
.
2021;52(8):691.
doi: 10.1159/000517908.
Epub 2021 Aug 18.
Authors
Mahmoud Nassar
1
,
Mohammed Elshafey
2
,
Carlos Gonzalez
1
,
Nso Nso
1
,
Mamdouh Mahdi
3
,
Ingi Elsayed
4
Affiliations
1
Medicine Department, Icahn School of Medicine at Mount Sinai/NYC Health + Hospitals Queens, New York, New York, USA.
2
Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
3
Professor of Nephrology, Dean of Faculty of Medicine, Helwan University, Cairo, Egypt.
4
Renal Department, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom.
PMID:
34515034
DOI:
10.1159/000517908
No abstract available
Publication types
Letter
Comment
MeSH terms
Graft Rejection / prevention & control
Graft Survival
Humans
Induction Chemotherapy
Kidney Transplantation*